NRF2 upregulation by CDDO-Me protects AC16 human cardiomyocytes against doxorubicin-induced toxicity.
James A. Roberts, Michael Batie, Amy H. Ponsford, Jonathan Poh, Benjamin J. Hewitt, Hannah F. Botfield, Lisa J. Hill, Christopher M. Sanderson, Sónia Rocha, Parveen Sharma
This study shows that CDDO-Me activates NRF2 to protect AC16 human cardiomyocytes from doxorubicin-induced toxicity by modulating p53 signaling, apoptosis, and ferroptosis.
Biomedicine & Pharmacotherapy · Dec 19, 2025Peer-reviewedPharmacology & Toxicology